Archive

• AXA IM Alts invests CHF 14m in vaccine developer

  09 October 2023

  Equity investment in LimmaTech will help develop vaccines to pathogens linked to antimicrobial resistance

• Axa commits $200m to affiliate's PE healthcare strategy

  04 April 2022

  Axa IM Alts targets $500m commitments